Literature DB >> 26606129

Dapsone as Second-Line Treatment for Cutaneous Lupus Erythematosus? A Retrospective Analysis of 34 Patients and a Review of the Literature.

Martin Klebes1, Nora Wutte, Elisabeth Aberer.   

Abstract

BACKGROUND: A variety of therapeutic options have been reported for cutaneous lupus erythematosus (CLE); one of these is dapsone. However, no high priority has been given to this drug.
OBJECTIVE: To determine whether dapsone is an effective and safe treatment alternative in patients with LE.
METHODS: We reviewed the literature and analyzed retrospectively 34 CLE patients who were treated with dapsone as monotherapy or combined with antimalarials. We assessed the course of the disease under treatment, response, concomitant treatment and side effects.
RESULTS: Six patients went into remission, 14 patients improved, and in 6 patients disease remained constant during the observation period. Dapsone was discontinued in 9 patients: in 4 due to reversible side effects and in 5 patients due to poor efficacy.
CONCLUSION: Our data confirm that dapsone with/without antimalarials is effective in more than 50% of patients with CLE and could be used as second-line therapy for CLE.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26606129     DOI: 10.1159/000441054

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  7 in total

Review 1.  Emerging Technologies to Target Drug Delivery to the Skin - the Role of Crystals and Carrier-Based Systems in the Case Study of Dapsone.

Authors:  Gabriela Schneider-Rauber; Debora Fretes Argenta; Thiago Caon
Journal:  Pharm Res       Date:  2020-11-09       Impact factor: 4.200

Review 2.  Cutaneous lupus erythematosus: updates on pathogenesis and associations with systemic lupus.

Authors:  Jasmine N Stannard; J Michelle Kahlenberg
Journal:  Curr Opin Rheumatol       Date:  2016-09       Impact factor: 5.006

Review 3.  Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases.

Authors:  Hideyuki Ujiie; David Rosmarin; Michael P Schön; Sonja Ständer; Katharina Boch; Martin Metz; Marcus Maurer; Diamant Thaci; Enno Schmidt; Connor Cole; Kyle T Amber; Dario Didona; Michael Hertl; Andreas Recke; Hanna Graßhoff; Alexander Hackel; Anja Schumann; Gabriela Riemekasten; Katja Bieber; Gant Sprow; Joshua Dan; Detlef Zillikens; Tanya Sezin; Angela M Christiano; Kerstin Wolk; Robert Sabat; Khalaf Kridin; Victoria P Werth; Ralf J Ludwig
Journal:  Front Med (Lausanne)       Date:  2022-06-09

4.  In silico Analyses of Skin and Peripheral Blood Transcriptional Data in Cutaneous Lupus Reveals CCR2-A Novel Potential Therapeutic Target.

Authors:  Rama Dey-Rao; Animesh A Sinha
Journal:  Front Immunol       Date:  2019-03-29       Impact factor: 7.561

5.  Research Supporting a Pilot Study of Metronomic Dapsone during Glioblastoma Chemoirradiation.

Authors:  Richard E Kast
Journal:  Med Sci (Basel)       Date:  2021-02-16

Review 6.  An update on the management of refractory cutaneous lupus erythematosus.

Authors:  Alice Verdelli; Alberto Corrà; Elena Biancamaria Mariotti; Cristina Aimo; Valentina Ruffo di Calabria; Walter Volpi; Lavinia Quintarelli; Marzia Caproni
Journal:  Front Med (Lausanne)       Date:  2022-09-23

Review 7.  Cutaneous lupus erythematosus: A review of the literature.

Authors:  Stephanie Clare Blake; Benjamin Silas Daniel
Journal:  Int J Womens Dermatol       Date:  2019-07-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.